sulfasalazine has been researched along with Pneumonia in 7 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Pneumonia: Infection of the lung often accompanied by inflammation.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Events included eight patients with malignancies, two with pancytopenia taking methotrexate, three with septic arthritis, and two with septicaemias." | 3.71 | Monitoring and assessing the safety of disease-modifying antirheumatic drugs: a West Midlands experience. ( Bevan, J; Homer, D; Jobanputra, P; Maggs, F, 2002) |
| "A patient with ulcerative colitis developed skin allergy to sulfasalazine, manifested by rash urticaria and generalized angioedema." | 3.67 | Sulfasalazine pneumonitis. ( Averbuch, M; Hallak, A; Halpern, Z; Levo, Y; Topilsky, M, 1985) |
| "Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis." | 3.67 | Sulfasalazine-induced lupus erythematosus. ( Clementz, GL; Dolin, BJ, 1988) |
| "The main aim of this study was to examine the differences between triple therapy (T: SSZ and HCQ added to MTX) and etanercept (E) added to MTX with regard to the infectious and gastrointestinal (GI) adverse events (AEs) reported in The Rheumatoid Arthritis Comparison of Active Therapies Trial." | 2.84 | Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events. ( Brophy, MT; Chang, BH; Hannagan, K; O'Dell, JR; Quach, LT; Soe Thwin, S, 2017) |
| "We report a rare case of drug-induced pneumonitis, probably caused by salazosulfapyridine, showing a radiographic pattern of multiple pulmonary nodules and lymphadenopathy." | 1.33 | [A case of salazosulfapyridine-induced pneumonitis presenting with multiple pulmonary nodules and lymphadenopathy]. ( Kasai, S; Nishine, H; Nishiyama, H; Tokuda, H; Yoshikawa, M, 2006) |
| "A man with alleged Crohn's disease of the terminal ileum was started on sulfasalazine." | 1.27 | Sulfasalazine pneumonitis. ( Korelitz, BI; Yaffe, BH, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (57.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Quach, LT | 1 |
| Chang, BH | 1 |
| Brophy, MT | 1 |
| Soe Thwin, S | 1 |
| Hannagan, K | 1 |
| O'Dell, JR | 1 |
| Jobanputra, P | 1 |
| Maggs, F | 1 |
| Homer, D | 1 |
| Bevan, J | 1 |
| Kasai, S | 1 |
| Tokuda, H | 1 |
| Yoshikawa, M | 1 |
| Nishine, H | 1 |
| Nishiyama, H | 1 |
| Yaffe, BH | 1 |
| Korelitz, BI | 1 |
| Averbuch, M | 1 |
| Halpern, Z | 1 |
| Hallak, A | 1 |
| Topilsky, M | 1 |
| Levo, Y | 1 |
| Clementz, GL | 1 |
| Dolin, BJ | 1 |
| Klein, HP | 1 |
| Rupp, M | 1 |
| Thiele-Fischbach, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #551 - Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy[NCT00405275] | 353 participants (Actual) | Interventional | 2007-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Average difference between 48-week and Baseline DAS28.~The Disease Activity Score for 28 Joints (DAS28) is a well-validated composite outcome measure ranging from 2-10 (higher scores indicating more disease) that incorporates a tender and swollen joint count of 28 joints, a laboratory measure of systemic inflammation (ESR) and a patient-reported general assessment of health on a visual analog scale (ranging from 0-10cm) all into one measure.~Low disease activity is defined as DAS28 ≤ 3.2 units." (NCT00405275)
Timeframe: 48 weeks after baseline assessment
| Intervention | units on a scale (Mean) |
|---|---|
| Triple | -2.12 |
| Etanercept | -2.29 |
1 trial available for sulfasalazine and Pneumonia
| Article | Year |
|---|---|
Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events.
Topics: Abscess; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etaner | 2017 |
6 other studies available for sulfasalazine and Pneumonia
| Article | Year |
|---|---|
Monitoring and assessing the safety of disease-modifying antirheumatic drugs: a West Midlands experience.
Topics: Antirheumatic Agents; Arthritis, Infectious; Azathioprine; Drug Monitoring; Humans; Hypokalemia; Lun | 2002 |
[A case of salazosulfapyridine-induced pneumonitis presenting with multiple pulmonary nodules and lymphadenopathy].
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Female; Humans; Lymphatic Diseas | 2006 |
Sulfasalazine pneumonitis.
Topics: Adult; Cough; Crohn Disease; Dyspnea; Eosinophilia; Fever; Humans; Male; Pneumonia; Radiography; Sul | 1983 |
Sulfasalazine pneumonitis.
Topics: Angioedema; Colitis, Ulcerative; Desensitization, Immunologic; Drug Administration Schedule; Follow- | 1985 |
Sulfasalazine-induced lupus erythematosus.
Topics: Adult; Antibodies, Antinuclear; Cardiac Tamponade; Colitis, Ulcerative; Humans; Lupus Erythematosus, | 1988 |
[Drug-induced alveolitis caused by salazosulfapyridine].
Topics: Adult; Arthritis, Rheumatoid; Female; Humans; Pneumonia; Pulmonary Alveoli; Sulfasalazine; Time Fact | 1988 |